Veeva reported fourth quarter revenue of $836.0 million and non-GAAP EPS of $2.06, beating consensus estimates of $811.0 million and $1.92, respectively. For the full fiscal year 2026, total revenue grew 16% to $3.195 billion, with subscription revenue increasing by 17%.

Key Highlights

  • Subscription revenue from R&D and Quality Solutions grew approximately 21% year-over-year to $380.8 million, overtaking Commercial Solutions as the company's largest subscription segment.
  • The company reported continued progress on its Vault CRM migration, ending the year with 10 of the top 20 biopharma companies committed to the platform globally and over 125 customers now live.
  • Veeva issued first quarter 2027 guidance with total revenues projected between $855 and $858 million and updated its full fiscal year 2027 revenue guidance to between $3,585 and $3,600 million.